Therapies for chronic and end-organ diseases are often associated with systemic toxicity, and such conditions result in difficulty treating patients. RNA nanomedicine has demonstrated unprecedented advantages in the field of therapeutics through its selective organ targeting, personalized treatment option and safety. In this paper, we extensively discuss the current state of nanotechnology in regenerative medicine and how this unique combination of RNA nanomedicine and regenerative medicine can be leveraged for a successful end-organ and chronic disease therapy. More specifically, we have put forward strategies to specifically deliver RNA nanomedicine to target organs/tissues in chronic disease patients, design considerations for regenerative medicine RNA therapy versus RNA vaccines, and barriers to clinical translation. We further discuss the call to action short- and long-term goals in the field of regenerative RNA nanomedicine that could change the face of regenerative medicine in the coming years. Bakrania et al. reviews advances in RNA nanomedicine and regenerative medicine, outlining strategies for targeted RNA delivery and overcoming translational barriers. It identifies key challenges and proposes short- and long-term goals to accelerate clinical translation for chronic and end-organ diseases.
Bakrania et al. (Sat,) studied this question.